Several hedge funds and other institutional investors have recently modified their holdings of IQVIA (NYSE:IQV), including AlphaCrest Capital Management LLC, Veriti Management LLC, and Guggenheim Capital LLC. Hedge funds and other institutional investors currently own 86.20% of the company’s stock. IQVIA Holdings, Inc is a leading provider of analytics, technology solutions, and clinical research services to the healthcare industry. The company operates through three segments, namely Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions.
IQVIA (NYSE:IQV) Coverage Initiated at Truist Financial
Truist Financial, an equities research analyst, has recently initiated coverage on shares of IQVIA (NYSE:IQV – Get Rating) by setting a “buy” rating and a… According to MarketBeat.com, IQVIA has an average rating of “Moderate Buy,” with three research analysts giving the stock a hold rating and thirteen assigning a buy rating to the company.
Other Analysts’ Reports
JPMorgan Chase & Co. raised their price objective on IQVIA to $263.00 and gave the company an “overweight” rating. Meanwhile, Citigroup downgraded IQVIA from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $275.00 to $245.00. Robert W. Baird, on the other hand, lowered their target price on IQVIA from $266.00 to $260.00 and set an “outperform” rating on the stock. Cowen initiated coverage on IQVIA and gave it an “outperform” rating.
Shares of NYSE:IQV opened at $190.89 on Friday, with a market capitalization of $35.53 billion. The stock’s 1-year low is $165.75, and its 1-year high is $254.94. IQVIA’s fifty-day simple moving average is $218.94, while its two-hundred-day simple moving average is $208.67. The company has a current ratio of 0.89, a quick ratio of 0.89, and a debt-to-equity ratio of 2.18. IQVIA has a PE ratio of 33.43, a price-to-earnings-growth ratio of 1.92, and a beta of 1.40.
IQVIA’s Quarterly Earnings Data
On February 10th, IQVIA (NYSE:IQV – Get Rating) reported its quarterly earnings data, with the medical research company earning $2.78 per share for the quarter. This figure beat the consensus estimate of $2.76 by $0.02. The company’s return on equity was 31.88%, while its net margin was 7.57%. The business’s revenue for the quarter was $3.74 billion, compared to analysts’ expectations of $3.71 billion. Analysts forecast that IQVIA will post 9.46 EPS for the current fiscal year.
Insider Buying and Selling at IQVIA
There is no information provided in the given text regarding insider buying and selling at IQVIA.
Insider Selling Activity at IQVIA
Insider selling activity at IQVIA (NYSE:IQV) has been disclosed in recent filings with the Securities & Exchange Commission. Eric Sherbet, an insider at IQVIA, sold 1,000 shares of IQVIA stock in a transaction dated February 14th, with an average price of $230.00 per share, for a total transaction value of $230,000.00. Following the completion of the sale, Sherbet owns 17,053 shares of the company’s stock, valued at approximately $3,922,190. Additionally, Kevin C. Knightly, another insider at IQVIA, sold 4,446 shares of the company’s stock on February 16th at an average price of $225.61 per share, for a total transaction value of $1,003,062.06. Following the completion of the sale, Knightly owns 1,973 shares of the company’s stock, valued at $445,128.53.
The aforementioned transactions have been disclosed in legal filings with the Securities & Exchange Commission. Additional details regarding these transactions can be accessed through the following links:
-
Eric Sherbet’s sale on February 14th: this link
-
Kevin C. Knightly’s sale on February 16th: the SEC website
Institutional Inflows and Outflows
No information regarding institutional inflows and outflows is provided in the given text.
Institutional Investors Modify Their Holdings of IQV
Hedge funds and other institutional investors have recently modified their holdings of IQVIA (NYSE:IQV). AlphaCrest Capital Management LLC, for instance, boosted its stake in the medical research company by 754.2% in the third quarter and now owns 17,042 shares worth $3,087,000. Veriti Management LLC boosted its stake in IQVIA by 1.9% in the third quarter and now owns 7,882 shares worth $1,428,000. Guggenheim Capital LLC also increased its stake in IQVIA by 21.2% in the third quarter and now owns 12,955 shares worth $2,347,000. Other institutional investors who have modified their holdings of IQVIA include Greenup Street Wealth Management LLC and Nomura Asset Management Co. Ltd. Hedge funds and other institutional investors currently own 86.20% of the company’s stock.
About IQVIA
IQVIA Holdings, Inc is a leading provider of analytics, technology solutions, and clinical research services to the life sciences industry. The company operates through three segments, namely Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment provides critical information, technology solutions, and real-world solutions and services to the firm’s life science clients. For the latest news and analysts’ ratings for IQVIA, sign up for MarketBeat.com’s FREE daily email newsletter.
Don’t miss interesting posts on Famousbio
